pipette
ESEspañol

Structure-Based Design with Arylazopyrazoles to Enable High-Affinity Photoswitchable Inhibitors of N -Myristoyltransferase

Lisa Carina Dollhopf, Samuel Perrett, Dominic Schatz, Helena D. Pickford, Victoria Stomberg, Edward J. Bartlett, Wouter W. Kallemeijn, Josephine Walton, Nicole Deacon-Smith, Cade R. Morrison, Daria Berezina, Rosina S. L. Gibson, Sam Horrell, Andrew Bell, Peter Haycock, Philip J. Parsons, Edward W. Tate, Jasper J. van Thor, Matthew John Fuchter

Peer-reviewed journalClaims a big step

In the authors' words

Abstract Photopharmacology using photoswitches is a powerful way to reversibly control biological function with light, through the generation of photoswitchable synthetic ligands. While optimization of bioactive small molecules is increasingly driven by iterative experimental protein–ligand structures, structure-guided improvement in photoswitch photopharmacology using experimental structures remains rare. Here we report the development of the first photoswitchable inhibitors of the human enzyme N-myristoyltransferase 1 (HsNMT1), using an arylazopyrazole (AAP) as the switch motif. Through experimental structure-based design, we obtain inhibitors with single-digit nanomolar affinity for NMT, functional activity in cells, and good differential activity between E and Z photoswitch isomers. The availability of our highly potent ligands and protein–ligand structures, coupled with the excellent photoswitch properties of the AAP, allowed us to study the effect of protein binding on the switching events, including characterization of protein-bound Z → E photoisomerization kinetics for the first time. Overall, this study showcases the potential for structure-based design in photoswitch pharmacology, including understanding the dynamic consequences of target binding, paving the way for the development of advanced photopharmaceuticals.

Main resultThe abstract does not state a limitation.

In plain words AI summary

The researchers created the first light-activated inhibitors of the human enzyme N-myristoyltransferase 1. They used a molecular switch called arylazopyrazole and designed the inhibitors using experimental protein structures. The resulting inhibitors bind very tightly, work in living cells, and show different activity between the two switch states. For the first time, they measured how fast the switch changes shape when bound to the protein. This work demonstrates how structure-based design can advance light-controlled drugs.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Saturday, October 17. Journal of the American Chemical Society. Peer-reviewed journal.

DOI: 10.1021/jacs.6c15228